ZUBRIN 200 ANTI-INFLAMMATORY TABLETS FOR DOGS

国家: 澳大利亚

语言: 英文

来源: APVMA (Australian Pesticides and Veterinary Medicines Authority)

现在购买

资料单张 资料单张 (PIL)
20-06-2017
产品特点 产品特点 (SPC)
20-06-2017

有效成分:

TEPOXALIN

可用日期:

INTERVET AUSTRALIA PTY LIMITED

INN(国际名称):

tepoxalin(200mg/Tb)

药物剂型:

ORAL TABLET

组成:

TEPOXALIN UNGROUPED Active 200.0 mg/Tb

每包单位数:

10 Tablets; 30 Tablets; 60 Tablets

类:

VM - Veterinary Medicine

厂商:

INTERVET AUSTRALIA

治疗组:

DOG | BITCH | CASTRATE | PUPPY

治疗领域:

MUSCULOSKELETAL SYSTEM

疗效迹象:

ANTI-INFLAMMATORY AGENT | MUSCULOSKELETAL CONDITIONS | ANTIPYRETIC | ARTHRITIS | ARTHROSIS | BONE SORENESS | BRUISING | BURSITIS | EXTERNAL MYOPATHY | INFLAMATION OF SOFT TISSUES AN | INFLAMMATORY RHEUMATIC ARTHRIT | JOINT DISEASE | LIGAMENT SPRAINS | MUSCLE SORENESS | OSTEITIS | OSTEOARTHRITIS | PLATELET ACTIVITY | RHEUMATISM | SPRAINS | STRAINS | TENDON AND LIGAMENT SPRAINS | TENDON SPRAINS | TENDONITIS | TENOSYNOVITIS | TRAUMATIC JOINT AND CONNECTIVE | TRAUMATIC SWELLING

產品總結:

Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [ANTI-INFLAMMATORY AGENT, MUSCULOSKELETAL CONDITIONS]; Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [ANTI-INFLAMMATORY AGENT, MUSCULOSKELETAL CONDITIONS]; A non steroidal anti inflammatory for the reduction of inflammation and relief of pain associated with musculoskeletal disorders in dogs.

授权状态:

Registered

授权日期:

2023-07-01

产品特点

                                ________________________________________________________________________
Schering-Plough Corporation
Global Supply Chain
1095 Morris Avenue
Union, New Jersey 07083-7143
Telephone (908) 298-4000
ZUBRIN
 RAPIDLY-DISINTEGRATING TABLETS
(EX000034)
This product is exempt from [Material] Safety Data Sheet requirements.
The following regional exemptions apply:
United States:
According to the OSHA Hazard Communication Standard [29 CFR §
1910.1200 (b) (6) (vii)], an MSDS is
not required for any drug when it is in the solid, final form (_e.g_.
tablets or pills).
European Union:
According to the European Union Commission Directive 2001/58/EC of 27
July 2001, as it relates to
Directive 1999/45/EC [Article 1.5.a], an SDS is not required for
medicinal products in the finished state,
intended for the final user.
Canada:
According to the WHMIS Hazardous Product Act [Part II Controlled
Products 12.b], an MSDS is not
required for any drug within the meaning of the _Food and Drugs Act._
If you have any questions or need assistance, please call
Schering-Plough Animal Health
Corporation at 800- 932-0473. Many Schering-Plough Animal Health
[Material] Safety Data
Sheets may be obtained through the MSDS HelpLine at 800-770-8878 or
from the S-P MSDS
website at www.schering-ploughmsds.com.
Technical inquiries for adverse events in animals for Schering-Plough
Animal Health Products may
be addressed to Schering-Plough Animal Health Technical Services:
For Small Animals and Horses (800) 224-5318
For Livestock (800) 211-3573
For Poultry (800) 219-9286
Sincerely,
Global Safety & Environmental Affairs
Schering-Plough Corporation
Schering-Plough
Global Safety & Environmental Affairs
                                
                                阅读完整的文件